Going Beyond the Cookie-Cutter Approach: Individualizing Therapeutic Decisions in CML

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: July 07, 2015
Expiration Date: July 07, 2016

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Join two world-leading CML clinical care experts, Stuart Goldberg, MD, associate clinical professor of medicine within the Division of Leukemia at the John Theurer Cancer Center in Hackensack, New Jersey, and Harry Erba, MD, professor of medicine and the director of hematologic malignancies at the University of Alabama at Birmingham, in a real-world case-based discussion of their experiences in caring for CML patients in their practice and in particular, how they go beyond the “cookie-cutter” approach to patient care, including monitoring, treatment selection, and consideration of side effects associated with each of the available TKIs in selecting therapy to ensure optimized individual patient outcomes.

Target Audience

This activity is designed for hematologists, oncologists, and associated multidisciplinary clinical specialists who provide care to patients with CML.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Compare and contrast first- and second-generation TKIs for the treatment of CML, focusing on efficacy and side-effect profiles and the remaining outstanding clinical questions
  • Describe the role of comorbidities and factors that may impact adherence to therapy in treatment selection for CML, differentiating between those that can be managed and those that, if not addressed, may have a negative impact on continuation of treatment and outcomes
  • Outline a process for identifying an effective therapeutic strategy for the individual patient with CML

Agenda

Going Beyond the Cookie-Cutter Approach: Individualizing Therapeutic Decisions in CMLStuart L. Goldberg, MD, Harry P. Erba, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through July 7, 2016. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Stuart L. Goldberg, MD
Division of Leukemia
John Theurer Cancer Center
Hackensack, New Jersey

Dr. Stuart Goldberg received his medical degree from Pennsylvania State University, Milton S. Hershey Medical Center. He completed his internal medicine residency and his hematology-oncology fellowship at George Washington University Medical Center. He also completed a bone marrow transplantation fellowship at Fred Hutchinson Cancer Research Center. Dr. Goldberg is a part of the Division of Leukemia, John Theurer Cancer Center in Hackensack, New Jersey.

Dr. Goldberg specializes in medical oncology and leukemia, and is board certified in medical oncology, hematology and internal medicine. He is a member of the American College of Physicians, American Society of Blood and Marrow Transplantation, American Society of Hematology, American Society of Clinical Oncology, Eastern Cooperative Oncology Group, Southwest Oncology Group, and the Myelodysplastic Foundation, among others. Dr. Goldberg specializes in treating all types of leukemia and myelodysplastic syndromes with a variety of treatment modalities, including chemotherapy and stem cell transplantation.

Harry P. Erba, MD, PhD
Professor, Internal Medicine
Director, Hematologic Malignancy Program
University of Alabama at Birmingham
Birmingham, Alabama

Dr. Harry Erba received his medical degree and doctorate in biophysics from Stanford University. He completed an internship and residency in internal medicine, as well as a fellowship in hematology/oncology at the Brigham and Women's Hospital, Harvard Medical School. Dr. Erba is currently professor of internal medicine at the University of Alabama at Birmingham (UAB). In addition, he serves as the director of the Hematologic Malignancy Program and is the associate director for Clinical Research in the UAB Comprehensive Cancer Center.

Dr. Erba has been an active member in the SWOG (formerly, Southwest Oncology Group) Leukemia Committee for over a decade. He was appointed chairman of the SWOG Leukemia Committee and now serves on the NCI Leukemia Steering Committee. He has also served on the National Comprehensive Cancer Network (NCCN) Practice Guidelines Committees for acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and myeloid growth factors. Dr. Erba has focused on the assessment of novel therapies in acute myeloid leukemia, myelodysplastic syndromes, chronic myeloid leukemia, and other myeloproliferative neoplasms. He has been involved in numerous clinical trials in these hematologic malignancies, led many national trials as a chair or co-chair, and played major roles in the development of several new drugs.

Accreditation

CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-15-026-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 15-026-016

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Stuart Goldberg has received honoraria related to speakers’ bureau activities from ARIAD, Bristol-Myers Squibb Company, and Novartis. He has received grant support related to research activities from ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer Inc. Dr. Goldberg has been employed by COTA (Cancer Outcomes Tracking Analysis).

Dr. Harry Erba has received consultant fees from Amgen Inc.; ARIAD Pharmaceuticals, Inc.; Celgene Corporation; Incyte Corporation; Novartis AG; Pfizer Inc.; Seattle Genetics, Inc.; and Sunesis Pharmaceuticals, Inc., as well as honoraria related to speakers’ bureau activities from Celgene, Incyte, and Novartis. He has received grant support related to research activities from Amgen; Astellas Pharma US, Inc.; Celator Pharmaceuticals, Inc.; Takeda Oncology; and Seattle Genetics, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Goldberg and Dr. Erba have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Goldberg and Dr. Erba have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managingcml.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from ARIAD Pharmaceuticals, Inc., Novartis, and Teva Pharmaceuticals.

©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.